RU2020112302A - Соединения для уменьшения вязкости биологических композиций - Google Patents
Соединения для уменьшения вязкости биологических композиций Download PDFInfo
- Publication number
- RU2020112302A RU2020112302A RU2020112302A RU2020112302A RU2020112302A RU 2020112302 A RU2020112302 A RU 2020112302A RU 2020112302 A RU2020112302 A RU 2020112302A RU 2020112302 A RU2020112302 A RU 2020112302A RU 2020112302 A RU2020112302 A RU 2020112302A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- seq
- paragraphs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554134P | 2017-09-05 | 2017-09-05 | |
| US62/554,134 | 2017-09-05 | ||
| PCT/US2018/048995 WO2019050780A1 (en) | 2017-09-05 | 2018-08-31 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020112302A true RU2020112302A (ru) | 2021-10-06 |
| RU2020112302A3 RU2020112302A3 (https=) | 2021-10-20 |
Family
ID=65634495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020112302A RU2020112302A (ru) | 2017-09-05 | 2018-08-31 | Соединения для уменьшения вязкости биологических композиций |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200206350A1 (https=) |
| EP (1) | EP3678700B1 (https=) |
| JP (1) | JP2020532562A (https=) |
| KR (1) | KR20200051687A (https=) |
| CN (1) | CN111107873A (https=) |
| AU (1) | AU2018328015A1 (https=) |
| BR (1) | BR112020004325A2 (https=) |
| CA (1) | CA3074565A1 (https=) |
| MX (1) | MX2020002429A (https=) |
| RU (1) | RU2020112302A (https=) |
| WO (1) | WO2019050780A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体の製剤および抗lag3抗体と抗pd-1抗体との共製剤 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN114507227B (zh) * | 2020-11-17 | 2024-06-21 | 中国医学科学院药物研究所 | 苯并异噻唑类化合物、及其制法和药物组合物与用途 |
| AU2022212007A1 (en) | 2021-01-29 | 2023-09-07 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| CN120225565A (zh) * | 2022-04-29 | 2025-06-27 | 默沙东有限责任公司 | 抗ilt4抗体或其抗原结合片段的药物制剂及其使用方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0144290A3 (de) * | 1983-12-01 | 1987-05-27 | Ciba-Geigy Ag | Substituierte Aethylendiaminderivate |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| CN1252130C (zh) * | 2002-04-01 | 2006-04-19 | 北京键凯科技有限公司 | 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物 |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| CN100543063C (zh) * | 2006-04-03 | 2009-09-23 | 中国科学院过程工程研究所 | 氨基酸端基聚乙二醇及其制备方法 |
| EP2230312A1 (en) * | 2009-03-19 | 2010-09-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Probe compound for detecting and isolating enzymes and means and methods using the same |
| CN102740888B (zh) * | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| WO2011160024A2 (en) * | 2010-06-17 | 2011-12-22 | Fuzians Biomedicals, Inc. | Compounds useful as antiviral agents, compositions, and methods of use |
| PT2691112T (pt) * | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| CN102532319A (zh) * | 2011-12-28 | 2012-07-04 | 暨南大学 | 二硫键稳定的抗bFGF人源双链抗体及其制备方法与应用 |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| CN102964588A (zh) * | 2012-11-09 | 2013-03-13 | 河南工业大学 | 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用 |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
-
2018
- 2018-08-31 AU AU2018328015A patent/AU2018328015A1/en not_active Abandoned
- 2018-08-31 WO PCT/US2018/048995 patent/WO2019050780A1/en not_active Ceased
- 2018-08-31 CA CA3074565A patent/CA3074565A1/en not_active Abandoned
- 2018-08-31 RU RU2020112302A patent/RU2020112302A/ru unknown
- 2018-08-31 EP EP18854741.8A patent/EP3678700B1/en active Active
- 2018-08-31 JP JP2020512875A patent/JP2020532562A/ja active Pending
- 2018-08-31 BR BR112020004325-7A patent/BR112020004325A2/pt not_active IP Right Cessation
- 2018-08-31 CN CN201880057465.7A patent/CN111107873A/zh active Pending
- 2018-08-31 KR KR1020207009463A patent/KR20200051687A/ko not_active Withdrawn
- 2018-08-31 US US16/644,107 patent/US20200206350A1/en not_active Abandoned
- 2018-08-31 MX MX2020002429A patent/MX2020002429A/es unknown
-
2022
- 2022-06-29 US US17/809,733 patent/US20220378916A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN111107873A (zh) | 2020-05-05 |
| WO2019050780A1 (en) | 2019-03-14 |
| US20200206350A1 (en) | 2020-07-02 |
| EP3678700A1 (en) | 2020-07-15 |
| BR112020004325A2 (pt) | 2020-10-06 |
| KR20200051687A (ko) | 2020-05-13 |
| EP3678700A4 (en) | 2021-04-28 |
| EP3678700B1 (en) | 2024-06-19 |
| MX2020002429A (es) | 2020-07-13 |
| CA3074565A1 (en) | 2019-03-14 |
| RU2020112302A3 (https=) | 2021-10-20 |
| JP2020532562A (ja) | 2020-11-12 |
| US20220378916A1 (en) | 2022-12-01 |
| AU2018328015A1 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020112302A (ru) | Соединения для уменьшения вязкости биологических композиций | |
| JP2020532562A5 (https=) | ||
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| US12384847B2 (en) | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen | |
| JP6444871B2 (ja) | 抗プロラクチン受容体抗体製剤 | |
| KR101320198B1 (ko) | 신생물의 치료를 위한 조성물 및 방법 | |
| JP2024042697A (ja) | 眼疾患を治療するための方法 | |
| TWI457134B (zh) | Rheumatoid arthritis treatment | |
| US10010513B2 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| PE20200513A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| JP2017534638A (ja) | 眼疾患を処置する方法 | |
| KR20080064154A (ko) | 췌도 이식에 있어서의 이식 췌도 장애 억제제 | |
| WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
| JP2013527176A (ja) | 高濃度抗体製剤 | |
| US20250136706A1 (en) | Methods For Prevention Of Graft Rejection In Xenotransplantation | |
| EA015173B1 (ru) | Комбинированная терапия с использованием антител к egfr и her2 | |
| BR112015006189B1 (pt) | Uso de um anticorpo anti-gm-csf | |
| EP4007640A1 (en) | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics | |
| JP2017105754A (ja) | 低粘度抗体組成物 | |
| US20100330093A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| CN105813637A (zh) | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 | |
| WO2022109302A1 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| US20220233631A1 (en) | Stable formulation of cetrorelix | |
| TW202033179A (zh) | 包含抗ox40抗體的製劑、其製備方法及其用途 | |
| JP6224586B2 (ja) | 注射用製剤 |